Video
Dr. Packiam on background of study of sequential intravesical chemo in BCG-naïve NMIBC
Author(s):
Video Player is loading.
Vignesh Packiam, MD, explains the background of the study, “Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer,” which was published in the Journal of Urology. Packiam is a clinical assistant professor of Urology, Department of Urology, University of Iowa Hospitals and Clinics.
Related Videos
Laura Davis, MD, on link between microplastics and bladder cancer
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
Expert discusses the NMIBC trials landscape
John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Study data point to gender disparities in oncology research citations
Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
Related Content
